Arbutus Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Arbutus Biopharma Corp (ABUS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Arbutus Reports Third Quarter 2026 Financial Results and Provides Corporate Update Maintained strong financial position with cash, cash equivalents and marketable securities of $337.5M as of September 30, 2026, including receipt of cash dividend of $67.3M from Geneva
How this was made
The 30-second read
Why it matters
The earnings beat and cash buildup provide a catalyst for short‑term buying, while ongoing patent litigation adds long‑term risk.
Market read
First‑time disclosure of earnings, cash position, and FDA hold lift makes the article highly relevant for traders in biotech equities.
What to watch
Litigation costs and future regulatory hurdles for AB-101 could temper upside.
Arbutus reports Q3 2026 net income of $59.1 million, driven by $67.3 million of dividend income from Genevant, alongside an operating loss and $337.5 million in cash, cash equivalents and marketable securities
Reported net income of $59,115 thousand (GAAP) sits alongside a loss from operations of $(10,494) thousand and total revenue of $299 thousand. The net income is built on the Dividend income line of $67,252 thousand, which the filing describes as a distribution of Genevant's earnings tied to the Moderna Noncontingent Settlement Payment. Cash of $337.5 million is stated, and $230 million was returned in the tender offer, leaving a $230,000 thousand repurchase obligation on the September 30, 2026 balance sheet.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenue, three months ended Sept 30, 2026GAAP | $299K | – | decrease of $0.2 million (as stated in MD&A) |
| Total revenue, nine months ended Sept 30, 2026GAAP | $180.4M | – | – |
| Collaborations and licenses revenue, three months ended Sept 30, 2026GAAP | $158K | – | – |
| Collaborations and licenses revenue, nine months ended Sept 30, 2026GAAP | $564K | – | – |
| License revenue from Genevant, nine months ended Sept 30, 2026GAAP | $179.4M | – | – |
| Non-cash royalty revenue, three months ended Sept 30, 2026GAAP | $141K | – | – |
| Non-cash royalty revenue, nine months ended Sept 30, 2026GAAP | $502K | – | – |
| Research and development expenses, three months ended Sept 30, 2026GAAP | $2.62M | – | decrease of $3.2 million (as stated in MD&A) |
| Research and development expenses, nine months ended Sept 30, 2026GAAP | $9.63M | – | – |
| General and administrative expenses, three months ended Sept 30, 2026GAAP | $7.96M | – | – |
| General and administrative expenses, nine months ended Sept 30, 2026GAAP | $17.71M | – | – |
| Change in fair value of contingent consideration, three months ended Sept 30, 2026GAAP | $221K | – | – |
| Restructuring costs, three months ended Sept 30, 2026GAAP | dash (no amount printed) | – | – |
| Restructuring costs, nine months ended Sept 30, 2026GAAP | dash (no amount printed) | – | – |
| Total operating expenses, three months ended Sept 30, 2026GAAP | $10.79M | – | – |
| Total operating expenses, nine months ended Sept 30, 2026GAAP | $27.99M | – | – |
| (Loss) income from operations, three months ended Sept 30, 2026GAAP | −$10.49M | – | – |
| (Loss) income from operations, nine months ended Sept 30, 2026GAAP | $152.4M | – | – |
| Dividend income, three months ended Sept 30, 2026GAAP | $67.25M | – | – |
| Dividend income, nine months ended Sept 30, 2026GAAP | $67.25M | – | – |
| Interest income, three months ended Sept 30, 2026GAAP | $2.37M | – | – |
| Interest income, nine months ended Sept 30, 2026GAAP | $4.03M | – | – |
| Interest expense, three months ended Sept 30, 2026GAAP | −$11K | – | – |
| Interest expense, nine months ended Sept 30, 2026GAAP | −$46K | – | – |
| Foreign exchange gain (loss), three months ended Sept 30, 2026GAAP | −$2K | – | – |
| Foreign exchange gain (loss), nine months ended Sept 30, 2026GAAP | −$16K | – | – |
| Total other income, three months ended Sept 30, 2026GAAP | $69.61M | – | – |
| Total other income, nine months ended Sept 30, 2026GAAP | $71.22M | – | – |
| Net income (loss), three months ended Sept 30, 2026GAAP | $59,115 thousand (stated as $59.1 million in the text) | – | – |
| Net income (loss), nine months ended Sept 30, 2026GAAP | $223.7M | – | – |
| Net income (loss) per common share, basic, three months ended Sept 30, 2026GAAP | $0.30 | – | – |
| Net income (loss) per common share, diluted, three months ended Sept 30, 2026GAAP | $0.30 | – | – |
| Net income (loss) per common share, basic, nine months ended Sept 30, 2026GAAP | $1.14 | – | – |
| Net income (loss) per common share, diluted, nine months ended Sept 30, 2026GAAP | $1.13 | – | – |
| Net cash provided by (used in) operating activities, nine months ended Sept 30, 2026GAAP | $225,684 thousand (stated as $225.7 million of net cash from operating activities in the text) | – | – |
| Cash, cash equivalents and marketable securities, as of Sept 30, 2026other | $337.5M | – | – |
| Capital returned to shareholders via modified Dutch Auction tender offer, early October 2026other | $230M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Collaborations and licenses (revenue line)Prior-year three-month figure printed as $280 thousand. Nine-month figure printed as $564 thousand against $11,809 thousand. The filing gives no driver for this line beyond the total revenue explanation. | $158 thousand, three months ended Sept 30, 2026 | – | – |
| License revenue from Genevant (revenue line)The filing prints no three-month amount for this line. The nine-month amount is printed on this line in the statement of income and loss, and the filing does not give a separate narrative for it. | dash (no amount printed), three months ended Sept 30, 2026; $179,373 thousand, nine months ended Sept 30, 2026 | – | – |
| Non-cash royalty revenue (revenue line)Prior-year three-month figure printed as $249 thousand. The filing states that total revenue decreased due primarily to a decrease in license royalty revenues, primarily due to a decline in Alnylam's sales of ONPATTRO. The filing does not tie this line to that explanation by name. | $141 thousand, three months ended Sept 30, 2026 | – | – |
Capital returns
- Modified Dutch Auction tender offer completed in early October 2026, returning $230 million of capital to shareholders (filing).
- The Company purchased 46 million common shares for cancellation at $5.00 per share in the Offer, representing approximately 23% of its issued and outstanding common shares as of September 29, 2026 (filing).
- Balance sheet at Sept 30, 2026 shows Obligation to repurchase shares of $230,000 thousand within total current liabilities of $241,933 thousand.
- Net cash provided by financing activities, nine months ended Sept 30, 2026: $19,473 thousand, against $4,081 thousand in the prior-year nine months. The filing attributes the nine-month proceeds to stock option exercises of $19.3 million.
What drove it
- Total revenue for the quarter decreased, which the filing attributes primarily to a decrease in license royalty revenues, primarily due to a decline in Alnylam's sales of ONPATTRO (company explanation).
- Research and development expenses decreased, which the filing attributes primarily to cost savings from the decisions to reduce the workforce and discontinue in-house scientific research, as well as lower clinical trial costs as studies neared completion (company explanation).
- General and administrative expenses increased, which the filing attributes primarily to higher employee compensation-related expenses driven by one-time cash bonuses paid to executives in consideration of efforts associated with the Moderna Settlement Agreement (company explanation).
- Restructuring costs were nil in the quarter (dash printed), against $98 thousand in the prior-year quarter.
- Dividend income of $67,252 thousand from Genevant appears in other income for the quarter. The filing describes it as a cash dividend received in September 2026 representing a distribution of Genevant's earnings in connection with the Noncontingent Settlement Payment.
- Moderna paid $950 million in July 2026 as the Noncontingent Settlement Payment. The Company received $178.4 million as its share, including reimbursement of litigation costs, in July 2026.
Concerns
- Loss from operations of $(10,494) thousand for the quarter, against $(8,659) thousand in the prior-year quarter. Net income for the quarter depends on the Dividend income line of $67,252 thousand within total other income of $69,609 thousand.
- Total revenue for the quarter was $299 thousand, against $529 thousand a year earlier, with royalty and collaboration revenue lines both lower.
- The filing reports $230,000 thousand of obligation to repurchase shares on the balance sheet at Sept 30, 2026, which was settled in early October 2026 through the tender offer.
- Moderna's additional $1.3 billion payment is contingent on an appellate ruling on the Moderna §1498 Appeal. The filing states that a decision is forthcoming after oral argument on November 5, 2026.
- The filing states that the Company's three-month operating expenses rose to $10,793 thousand from $9,188 thousand, with General and administrative expenses up to $7,955 thousand from $3,044 thousand.
What to watch
- Federal Circuit decision on the Moderna §1498 Appeal, which the filing says is forthcoming and which governs the contingent $1.3 billion payment.
- Next steps for AB-101 development in the United States following the FDA lifting the clinical hold on the IND application, which the filing says the Company is evaluating.
- Progress of the new Japanese lawsuits against Pfizer Japan Inc. and the amended Canadian lawsuit against Pfizer/BioNTech, as described in the filing.
- Whether General and administrative expenses return toward the prior-year level after the one-time cash bonuses, as the filing attributes the increase to them.
- Quarterly Report on Form 10-Q, which the filing states will be filed on November 10, 2026, for further detail on the Moderna settlement terms and the contingent payment.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities, current: $337,490 thousand at Sept 30, 2026, against $91,471 thousand at Dec 31, 2025.
- Total assets: $339,698 thousand at Sept 30, 2026, against $94,618 thousand at Dec 31, 2025.
- Total current liabilities: $241,933 thousand at Sept 30, 2026, against $6,006 thousand at Dec 31, 2025.
- Total stockholders' equity: $85,746 thousand at Sept 30, 2026, against $76,576 thousand at Dec 31, 2025.
- Accounts payable and accrued liabilities: $11,605 thousand at Sept 30, 2026, against $5,459 thousand at Dec 31, 2025.
- Liability related to sale of future royalties: $2,981 thousand at Sept 30, 2026, against $3,442 thousand at Dec 31, 2025.
- Contingent consideration: $9,038 thousand at Sept 30, 2026, against $8,395 thousand at Dec 31, 2025.
- Net cash provided by investing activities, nine months ended Sept 30, 2026: $1,042 thousand, against $16,941 thousand in the prior-year nine months.
- Cash and cash equivalents, end of period: $264,191 thousand, plus investments in marketable securities of $73,299 thousand, equals $337,490 thousand (statement of cash flows).
- The filing states that cash, cash equivalents and investments in marketable securities were $337.5 million as of Sept 30, 2026, compared with $91.5 million as of Dec 31, 2025.
Analysis
Arbutus reports a third quarter of 2026 with total revenue of $299 thousand (GAAP), against $529 thousand a year earlier. The filing attributes the decline primarily to lower license royalty revenues, tied to a decline in Alnylam's sales of ONPATTRO. Collaborations and licenses revenue was $158 thousand against $280 thousand, and non-cash royalty revenue was $141 thousand against $249 thousand. The quarter's revenue base is small, so the top line offers little read on demand for the Company's programs.
Cost lines moved in different directions. Research and development expenses fell to $2,617 thousand from $5,778 thousand, which the filing attributes to workforce reduction, the discontinuation of in-house scientific research and lower clinical trial costs. General and administrative expenses rose to $7,955 thousand from $3,044 thousand, which the filing attributes primarily to one-time cash bonuses paid to executives for work associated with the Moderna Settlement Agreement. Total operating expenses were $10,793 thousand against $9,188 thousand, and the loss from operations was $(10,494) thousand against $(8,659) thousand. No restructuring costs were recorded in the quarter, against $98 thousand a year earlier.
Net income for the quarter was $59,115 thousand (GAAP), or $0.30 per basic and diluted share, against a net loss of $(7,742) thousand, or $(0.04) per share. The net income depends on the Dividend income line of $67,252 thousand, which sits within total other income of $69,609 thousand. The filing describes that dividend as a distribution of Genevant's earnings tied to the Moderna Noncontingent Settlement Payment. For the nine months, the statement of income and loss prints License revenue from Genevant of $179,373 thousand and an income from operations of $152,450 thousand, against a loss from operations of $(32,870) thousand a year earlier. The nine-month and quarter comparisons therefore differ in composition, and this read does not extend the three-month operating loss to the nine-month figure.
On the balance sheet, cash, cash equivalents and marketable securities were $337.5 million at Sept 30, 2026, against $91.5 million at Dec 31, 2025. The balance sheet carries an obligation to repurchase shares of $230,000 thousand, which the Company settled through the modified Dutch Auction tender offer in early October 2026. In that offer the Company bought 46 million common shares at $5.00 per share, which the filing says is approximately 23% of shares outstanding as of September 29, 2026. Net cash provided by operating activities for the nine months was $225,684 thousand, against a use of $(34,957) thousand a year earlier, and the filing also cites $19.3 million of option exercise proceeds.
The filing gives no quantitative guidance for the coming period, so this read has no outlook comparison. The qualitative outlook points to the pending Federal Circuit decision on the Moderna §1498 Appeal, which governs an additional $1.3 billion contingent payment, and to the evaluation of next steps for AB-101 after the FDA lifted the clinical hold on its IND application. The figures to weigh most are the reliance of Q3 net income on one dividend line, the operating loss at the quarter level, and the size of the contingent Moderna payment relative to the reported cash balance.
Management, verbatim
This has been a busy and productive quarter for the Arbutus team.
Lindsay Androski, President and CEO, Arbutus
I would like to congratulate our finance team, which successfully returned a substantial portion of Moderna's first patent infringement payment to shareholders, and our R&D team, for achieving the lift of the 2023 U.S. FDA clinical hold on our oral PD-L1 inhibitor, AB-101, following a successful Phase 1 trial abroad.
Lindsay Androski, President and CEO, Arbutus
Not in the filing
stated, not guessed- Prior guidance or outlook: no previous release was provided, so no guidance comparison is made.
- Current-period guidance: the filing gives no quantitative revenue, operating expense, gross margin or tax rate guidance.
- Prior-quarter (Q2 2026) comparatives: the filing does not print a second-quarter 2026 figure, so all qoq_change and prior_quarter fields are null.
- Percentage changes: the filing prints dollar changes for some lines only and gives no percentage changes, so yoy_change fields are null except where the MD&A states a dollar change.
- Prior-year comparison for Cash, cash equivalents and marketable securities: the filing compares Sept 30, 2026 with Dec 31, 2025, not with the prior-year period, so prior_year is null on that row.
- Gross margin, cost of sales and tax lines: none are printed in the filing.
- Non-GAAP reconciliation: none is provided, so all reported figures are GAAP.
- Analyst consensus, price targets and share price reaction: not in the documents.
- Timing of the Federal Circuit decision on the Moderna §1498 Appeal: the filing says only that a decision is forthcoming.
- Driver for the Genevant license revenue nine-month figure and the Collaborations and licenses nine-month figure: the filing does not give a narrative explanation for these lines.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Arbutus Biopharma filed a Form 8‑K reporting its Q3 2026 financials and corporate updates, including a tender‑offer return of capital and FDA action.
Ticker impact
Q3 2026 results show net income of $59.1M, cash of $337.5M and FDA lift of clinical hold on AB-101.
upward pressure as investors price in stronger cash position and clinical progress.
The company posted a surprise profit, increased cash dramatically and removed a FDA hold, all first‑time disclosures.
Market effects
Positive signal for biotech firms with LNP technology and RNA therapeutics.
May lift sentiment for US biotech sector in Nasdaq.
Highlights ongoing patent battles in mRNA space, relevant to global pharma investors.
Counterpoint
Profit may be one‑off from settlement cash; underlying pipeline still early stage.
Key entities
- companyArbutus Biopharma Corp
Clinical‑stage biotech focused on infectious disease and LNP technology.
- partnerGenevant Sciences
Co‑owner of LNP patents and settlement partner with Arbutus.
